DXB Square Logo
Dimerix
(ASX:DXB)


 

  Our Initial Entry
Price

Portfolio Initiation

5 Day VWAP
After Initiation

Current Price

Our Current Returns

ASX:DXB
$0.200
$0.400
Aug 16 2021
$0.348
$0.310
    55%

ASX:DXB
Our Current Returns
55%




Overview

📋 About: Dimerix Limited (ASX:DXB) is a biotech company that has developed a treatment for inflammatory diseases - such as kidney and respiratory diseases.

🌏 Macro Theme: After watching the COVID-19 pandemic unfold and the global attention on vaccine development, we believe the next decade will see significant investor interest in life sciences, human health and bio-technology.

Dimerix Company Milestones

✅ $20M Cap Raise @20c
✅ Investment from Biotech Fund Merchant
✅ Portfolio initiation

🔲 Funding 1
🔲 Funding 2
🔲 Unexpected Positive Announcement 1
🔲 Unexpected Positive Announcement 2
🔲 Unexpected Positive Announcement 3
🔲 New Technology Development 1
🔲 New Technology Development 2

FSGS Treatment (Main Bet)

✅ Phase III Study Design Complete
Study design approval from FDA
🔄 Ethics submission and site initiation for first sites
🔲 Phase III Trials Commenced: Study Period 1
🔲 First patient Recruited/Dosed
🔲 Patient Recruitment Update 1
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 Recruitment Complete
🔲 Interim Results
🔲 Phase III Trials Continue: Study Period 2
🔲 Patient Recruitment Update 1
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 Phase III Data collected for accelerate approvals
🔲 Accelerate Approvals Submitted
🔲 Accelerated Approvals Granted (H2 2024)
🔲 Drug Commercialised
🔲 Final Results eGFR (how well is the patient’s kidney functioning)
🔲 New Milestones Added

Covid-19 Treatment (Side Bet 1)

CLARITY 2.0: Respiratory Complications

✅Study Announced
✅Ethics Approval
🔄 Regulatory approval by DCGI
🔲 Patient Recruitment Update 1
🔲 Safety Threshold Met (80 Patients)
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 CLARITY Phase III Study Complete
🔲 Primary Endpoint Reporting
🔲 Emergency use granted
🔲 Drug Commercialised
🔲 New Milestones Added

Covid-19 Treatment (Side Bet 2)

ICU Patients with Pneumonia

✅ Patient Recruitment Commenced
Study Commenced
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 REMAP-CAP Phase III Study Complete
🔲 Primary Endpoint Reporting
🔲 Emergency use granted
🔲 Drug Commercialised

Investment Milestones for DXB

Initial Investment: @20c
🔲 Increase Investment
🔲 Increase Investment
🔲 Price increases 500% from initial entry
🔲 Price increases 1000% from initial entry
🔲 Price increases 2000% from initial entry
🔲 12 Month Capital Gain Discount
🔲 Free Carry
🔲 Take Profit
🔲 Hold remaining Position for next 2+ years

”Expected Company Milestones” are based on the company's publicly available execution plan and some assumptions made by our team on potential announcements that should de-risk the investment. “Our investment milestones” show our current long-term investment plan. Early stage investments are risky and there is no guarantee that the expected events will occur. The lists are not in sequential order.

Key

🔲 Expected Milestone
✅ Achieved Milestone
🟩 Above Average Result
🟨 Average (Expected) Result
🟧 Below Average Result
🟥 Negative Result
🌎 Macro Event
⚔️ Results from Other Company / Project
🔄 Progress Ongoing
[UPA] Unexpected Positive Announcement
[NEW] New Milestone Added



Our Past Commentary on Dimerix








Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X